339 related articles for article (PubMed ID: 27748765)
61. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
[TBL] [Abstract][Full Text] [Related]
62. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
63. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV
Cells; 2020 Mar; 9(3):. PubMed ID: 32155786
[TBL] [Abstract][Full Text] [Related]
64. Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.
Zhao Y; Laws MJ; Guillen VS; Ziegler Y; Min J; Sharma A; Kim SH; Chu D; Park BH; Oesterreich S; Mao C; Shapiro DJ; Nettles KW; Katzenellenbogen JA; Katzenellenbogen BS
Cancer Res; 2017 Oct; 77(20):5602-5613. PubMed ID: 28904064
[TBL] [Abstract][Full Text] [Related]
65. Hormonal modulation of ESR1 mutant metastasis.
Gu G; Tian L; Herzog SK; Rechoum Y; Gelsomino L; Gao M; Du L; Kim JA; Dustin D; Lo HC; Beyer AR; Edwards DG; Gonzalez T; Tsimelzon A; Huang HJ; Fernandez NM; Grimm SL; Hilsenbeck SG; Liu D; Xu J; Alaniz A; Li S; Mills GB; Janku F; Kittler R; Zhang XH; Coarfa C; Foulds CE; Symmans WF; Andò S; Fuqua SAW
Oncogene; 2021 Feb; 40(5):997-1011. PubMed ID: 33323970
[TBL] [Abstract][Full Text] [Related]
66. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
67. Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
Simigdala N; Pancholi S; Ribas R; Folkerd E; Liccardi G; Nikitorowicz-Buniak J; Johnston SR; Dowsett M; Martin LA
Br J Cancer; 2018 Aug; 119(3):313-322. PubMed ID: 29991699
[TBL] [Abstract][Full Text] [Related]
68. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
[TBL] [Abstract][Full Text] [Related]
69. Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI.
Mao C; Livezey M; Kim JE; Shapiro DJ
Sci Rep; 2016 Oct; 6():34753. PubMed ID: 27713477
[TBL] [Abstract][Full Text] [Related]
70. Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation.
Lipfert L; Fisher JE; Wei N; Scafonas A; Su Q; Yudkovitz J; Chen F; Warrier S; Birzin ET; Kim S; Chen HY; Tan Q; Schmidt A; Dininno F; Rohrer SP; Hammond ML; Rodan GA; Freedman LP; Reszka AA
Mol Endocrinol; 2006 Mar; 20(3):516-33. PubMed ID: 16223974
[TBL] [Abstract][Full Text] [Related]
71. An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
Scherer SD; Riggio AI; Haroun F; DeRose YS; Ekiz HA; Fujita M; Toner J; Zhao L; Li Z; Oesterreich S; Samatar AA; Welm AL
Breast Cancer Res; 2021 Oct; 23(1):100. PubMed ID: 34717714
[TBL] [Abstract][Full Text] [Related]
72. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
[TBL] [Abstract][Full Text] [Related]
73. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.
Jeselsohn R; Yelensky R; Buchwalter G; Frampton G; Meric-Bernstam F; Gonzalez-Angulo AM; Ferrer-Lozano J; Perez-Fidalgo JA; Cristofanilli M; Gómez H; Arteaga CL; Giltnane J; Balko JM; Cronin MT; Jarosz M; Sun J; Hawryluk M; Lipson D; Otto G; Ross JS; Dvir A; Soussan-Gutman L; Wolf I; Rubinek T; Gilmore L; Schnitt S; Come SE; Pusztai L; Stephens P; Brown M; Miller VA
Clin Cancer Res; 2014 Apr; 20(7):1757-1767. PubMed ID: 24398047
[TBL] [Abstract][Full Text] [Related]
74. Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination.
Parisian AD; Barratt SA; Hodges-Gallagher L; Ortega FE; Peña G; Sapugay J; Robello B; Sun R; Kulp D; Palanisamy GS; Myles DC; Kushner PJ; Harmon CL
Mol Cancer Ther; 2024 Mar; 23(3):285-300. PubMed ID: 38102750
[TBL] [Abstract][Full Text] [Related]
75. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
76. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein.
Weis KE; Ekena K; Thomas JA; Lazennec G; Katzenellenbogen BS
Mol Endocrinol; 1996 Nov; 10(11):1388-98. PubMed ID: 8923465
[TBL] [Abstract][Full Text] [Related]
77. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
78. Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
Suba Z
Recent Pat Anticancer Drug Discov; 2017; 12(2):136-147. PubMed ID: 28245776
[TBL] [Abstract][Full Text] [Related]
79. XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation.
Barua D; Abbasi B; Gupta A; Gupta S
Heliyon; 2020 Oct; 6(10):e05217. PubMed ID: 33088967
[TBL] [Abstract][Full Text] [Related]
80. MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.
Bobustuc GC; Smith JS; Maddipatla S; Jeudy S; Limaye A; Isley B; Caparas ML; Constantino SM; Shah N; Baker CH; Srivenugopal KS; Baidas S; Konduri SD
Mol Med; 2012 Sep; 18(1):913-29. PubMed ID: 22549111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
